Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing oxygen-containing organic compound
Reexamination Certificate
2006-01-03
2006-01-03
Mosher, Mary E. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing oxygen-containing organic compound
C435S139000, C435S147000, C530S387900, C530S388300, C530S389400
Reexamination Certificate
active
06982156
ABSTRACT:
Antibodies directed to SPICE and VCP which may be used for detection, prevention, and treatment of variola virus or vaccinia virus are provided. Recombinant SPICE and VCP proteins are also provided which are used for enhancing the immune response to variola or vaccinia virus and modulating of complement activation. Methods and kits for detecting nucleic acid sequences encoding SPICE and VCP are also provided.
REFERENCES:
patent: 5157110 (1992-10-01), Kotwal et al.
patent: 5843778 (1998-12-01), Rosengard et al.
patent: WO 93/19183 (1993-09-01), None
patent: WO 95/20660 (1995-08-01), None
patent: WO 99/44625 (1999-09-01), None
“Vaccinia (Smallpox) Vaccine Recommendations of the Immunization Practices Advisory Committee (ACIP).” MMWR 40(RR14):1-10, 1991.
Campbell et al., Methods and Immunology, W.A. Benjamin, Inc. 1964.
Cooper N.R., “Complement and Viruses”, The Human Complement System in Health and Disease, vol. 1, Editors Volanakis J.E. and Frank M.M. 393-407 Marcel Dekker, Inc. New York 1998.
Conry et al., “Immune Response to a Carcinoembryonic Antigen Polynucleotide Vaccine”, Cancer Research 1994 54:1164-1168.
Cox et al., “Bovine Herpesvirus 1:Immune Responses in Mice and Cattle Injected with Plasmid DNA”, Virology 1993 67(9): 5664-5667.
Dalmasso A.P., “Role of Complement in Graft Rejection”, In:The Complement System, vol. 1 (editors Rother, K., Till, G.O., & Hänsch, G.M.) Springer-Verlag, Berlin 1997 471-486.
Davis et al., “DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody”, Human Molecular Genetics 1993 2 (11):1847-1851.
DePraval et al., “Variability of Interchain Binding of Immunoglobulins” Nature 1970 228:930-932.
Dempsey et al., “C3d of Complement as a Molecular Adjuvant:Bridging Innate and Acquired Immunity”, Science 1996 271:348-350.
Donnelly et al., “Preclinical efficacy of a prototype DNA vaccine:Enhanced protection against antigenic drift in influenza virus”, Nature Medicine 1995 1 (6) : 583-587.
ELISA in Methods of Immunodiagnosis, 2nd Edition, Rose and Bigazzi, editors John Wiley & Sons 1980.
Fynan et al., “Use of DNA Encoding Influenza Hemagglutinin as an Avian Influenza Vaccine”, DNA and Cell Biology 1993 12(9):785-789.
Fynan et al., “DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations”, Proc. Natl. Acad. Sci. USA 1993 90:11478-11482.
Harlow and Lane—Antibodies: A Laboratory Manual—Cold Spring Harbor Laboratory, New York 1988 Chapter 14 553-612.
Isaacs et al., “Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence”, Proc. Natl. Acad. Sci. USA 1992 89:628-632.
Kalli et al., “Mapping of the C3b-binding Site of CR1 and Construction of a (CR1)2-F(ab′)2Chimeric Complement Inhibitor”, J. Exp. Med 1991 174:1451-1460.
Kennedy et al., “Protein-Protein Coupling Reactions and the Applications of Protein Conjugates”, Clinica Chimica Acta 1976 70:1-31.
Khaw et al., “Radiochemistry and Radiopharmaceuticals—Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen”, J. Nucl. Med. 1982 1011-1019.
Kitamura H., “Interspecies Incomatibilities of Complement Factors and Regulators”, In:The Complement System, vol. 1 (editors Rother, K., Till, G.O., & Hänsch, G.M.) Springer-Verlag, Berlin 1998.
Klickstein et al., “Identification of Distinct C3b and C4b Recogntiion Sites in the Human C3b/C4b Receptor (CR1, CD35) by Deletion Mutagenesis”, J. Exp. Med. 1988 168:1699-1711.
Köhler and Mulstein, “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature 1975 256:495-497.
Kotwal et al., “Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins”, Nature 1988 335:176-178.
Kotwal et al., “Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus”, Science 1990 250:827-830.
Krych et al., “Analysis of the Functional Domains of Complement Receptor Type 1 (C3b/C4b Receptor; CD35) by Substitution Mutagenesis”, J. Biol. Chem. 1994 269:13273-13278.
Krych et al., “Sites within the complement C3b/C4b receptor important for the specificity of ligand binding”, Proc. Natl. Acad. Sci. USA 1991 88:4353-4357.
Lachmann et al., “Complement and immunity to viruses”, Immunological Reviews 1997 159:69-77.
Lachmann P.J., “Microbial subversion of the immune response”, PNAS 2002 99(13):8461-8462.
Liszewski et al., “Regulatory Proteins of Complement” In:The Human Complement System in Health and Disease vol. 1 Editors Volanakis J.E. and Frank M.M. Marcel Dekker, Inc. New York 1998 149-166.
Massung et al., “Terminal Region Sequence Variations in Variola Virus DNA”, Virology 1996 221:291-300.
McKenzie et al., “Regulation of Complment Activity by Vaccinia Virus Complement-Control Protein”, J. Infect. Dis. 1992 166:1245-1250.
McPherson et al., PCR, A Practical Approach, IRL Press, Oxford, England 1991.
Montgomery et al., “Heterologous and Homologous Protection Agaisnt Influenza A by DNA Vaccination:Optimization of DNA Vectors”, DNA Cell Biol. 1993 12(9):777-783.
Moss B., “Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety”, Proc. Natl. Acad. Sci. USA 1996 93:11341-11348.
Mroczkowski et al., “Secretion of Thermostable DNA Polymerase Using a Novel Baculovirus Vector”, J. Biol. Chem. 1994 269(18):13522-13528.
Pangburn et al., “Human Complement C3b Inactivator:Isolation, Characterization, and Demonstration of an Absolute Requirement for the Serum Protein β1H for Cleavage of C3b and C4b in Solution”, J. Exp. Med. 1977 146:257-270.
Raz et al., “Intradermal gene immunization:The possible role of DNA uptake in the induction of cellular immunity to viruses”, Proc. Natl. Acad. Sci. USA 1994 91:9519-9523.
Remington's Pharmaceutical Sciences 16th edition Osol A., Editor Mack Easton, PA 1980.
Robinson et al., “Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA”, Vaccine 1993 11:957-960.
Ropp et al., “PCR Strategy for Identification and Differentiation of Smallpox and Other Orthopoxviruses”, J. Clin. Microbiol. 1995 33(8):2069-2076.
Rosengard et al., “Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP)”, Mol. Immunol. 1999 36:689-697.
Rosengard et al., “Variola virus immune evasion design:Expression of a highly efficient inhibitor of human complement”, PNAS 2002 99(13):8803-8813.
Ross et al., “C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge”, Nat. Immunol. 2000 1(2):127-131.
Ross et al., “Generation of Three Different Fragments of Bound C3 with Purified Factor 1 or Serum”, J. Immunol. 1982 129(5):2051-2060.
Sahu et al., “Interaction of Vaccinia Virus Complement Control Protein with Human Complement Proteins:Factor I-Mediated Degradation of C3b to iC3b1Inactivates the Alternative Complement Pathway1”, J. Immunol. 1998 160:5596-5604.
Schuurs et al., “Enzyme-Immunoassay”, Clin. Chim. Acta 1977 81:1-40.
Shchelkunov et al., “Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms”, FEBS Lett. 1993 319:80-83.
Sedegah et al., “Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein”, Proc. Natl. Acad. Sci. USA 1994 91:9866-9870.
Ulmer et al., “Heterologous Protection Against Influ
Licata & Tyrrell P.C.
Mosher Mary E.
Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods modulating variola and vaccinia virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods modulating variola and vaccinia virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods modulating variola and vaccinia virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557936